Therefore, the combination of mTOR inhibitors and hormone- or HER2-targeting therapies was believed to be a promising strategy for overcoming initial therapeutic resistance and for preventing the development of resistance in ER+/HER2+ breast cancer[26].There is an intimate relationship between FASN and mTOR. The gene discussed is MTOR; the disease is breast carcinoma.